Table 1.
[PART I. + II.] Main characteristics of all patients (n=417), according to treatment received (PART I.) and its association with observed SM (PART II.)
| PART I. | |||||
|---|---|---|---|---|---|
| Treatment type | Patients, n (%) |
males n (%) |
Age median, (range), mos |
Total treatment lengthd median, [range], mos |
Total follow up time median, [range], mos |
| Monotherapy | 136 (33) | 57 (42) | 49 (20–80) | 60 (2–240) | 95 (5.8–362) |
| Hydrea | 73 (53.7) | 34 | 67 (37–80) | 60 (6–216) | 73 (9.2–285) |
| Anagrelide | 14 (10.3) | 3 | 49 (25–78) | 78 (2–144) | 113 (9.9–297.4) |
| Interferon | 42 (31) | 12 | 45.5 (20–69) | 72 (2–240) | 98 (9.6–285) |
| Othersa | 7 (5) | 6 | 44 (23–67) | 72 (24–108) | 144 (47.5–362) |
|
Multiple treatments |
222 (53) | 83 (37) | 51 (15–84) | 108 (2–360) | 126 (0.2–340) |
| 2 linesb | 172 (77.5) | 63 | 52 (15–84) | 96 (2–324) | 123 (15.5–174) |
| 3 and more linesc | 50 (22.5) | 20 | 49 (16–72) | 132 (3–360) | 157 (7.7–474) |
| No treatment | 59 (14) | 24 (42) | 48 (15–83) | NA | 53.6 [0.2–314] |
| PART II. | |||||
|
Monotherapy, type, (n) |
Multiple treatments, (n) |
No treatment, (n) |
|||
|
SM type, number according to treatment |
B-NHL | DLBCL | HU (1) | 2 lines (2) | |
| BL | 3 lines (1) | ||||
| MCL | 3 lines (1) | (1) | |||
| MALT | (1) | ||||
| T-NHL | (1) | ||||
| GI tract | CRC | HU (1), INF (1) | 2 lines (1) | ||
| Cholangio | OTH (1) | ||||
| GYN (female) |
Breast | ANAGR (2) | 2 lines (1) | (1) | |
| SCC vulva | (1) | ||||
| GU tract | Prostate | HU (1) | (1) | ||
| Bladder | 2 lines (1) | ||||
| RCC | 2 lines (1) | ||||
| Lung | NSCLC | HU (2) | |||
| SCLC | HU (1) | ||||
| Melanoma | HU (2) | (1) | |||
| Thyroid Ca | (2) | ||||
| Sacroma | NFS | (1) | |||
| STS | 2 lines (1) | ||||
| NET | HU (1) | ||||
| SM, n (%) | Total | 13 (9.6) | 9 (4) | 10 (17) | |
| HU: ANAGR: INF: OTH |
9 (12): 2 (14): 1 (2.4): 1 (14) |
||||
| 2 lines: 3 lines | 7 (4): 2 (5) | ||||
|
Males with SM, n, (%) |
Total | 6 (46) | 4 (45) | 7 (70) | |
| HU: OTH |
5 (83) 1 (100) |
||||
| 2 lines: 3 lines | 2 (29): 2 (100) | ||||
|
Time from MPN dx to SM median, [range], mos |
Total | 62 [5–215] | 85 [14.5–128] | 73 [0.1–251] | |
| HU: ANAGR: INF: OTH |
49.5 [5–125]: 154 [140–168]: 62: 90.4 |
||||
| 2 lines: 3 lines |
85 [15–128]: 110 [79–141] |
||||
|
Treatment length before SM, median, [range], mos |
Total | 42 [2–216] | 26 [2–360] | NA | |
| HU: ANAGR: INF:OTH |
36 [2–216]: 2 [2–2]: 48: 72 |
||||
| 2 lines: 3 lines |
24 [24–96]: 105 [72–138] |
||||
Abbr.: HU=hydroxyurea, ANAGR= Anagrelide, INF= Interferon, OTH= Others, SM=secondary malignancy, DLBCL= Diffuse large cell lymphoma, MCL = Mantle cell lymphoma, MALT = Mucosa associated lymphoid tumor, BL = Burkitt lymphoma, CRC = Colorectal carcinoma, NET = Neuroendocrine carcinoma, NSCLC = Non-small cell lung carcinoma, SCLC = Small cell lung carcinoma, STS = Soft tissue sarcoma, RCC = Renal cell carcinoma, NFS = Neurofibrosarcoma, SCC = Squamous cell carcinoma
Imatinib (n=4), busulfan (n=2), 6-mercaptopurine (n=1)
Hydroxyurea + Anagrelide (n=85), Hydroxyurea +Interferon (n= 35), Anagrelide + Interferon (n=13), Hydroxyurea with other agents (n=29);
Hydroxyurea + Anagrelide + Interferon (n=20); all others (n=69)
Treatment length was known in 217 patients